Larimar Therapeutics, Inc. (LRMR)

$ 10
-0.27 (-2.63%)
-
Symbol LRMR
Price $ 10
Beta 0.823
Volume Avg. 0.05M
Market Cap 0.177B
Shares () -
52 Week Range 7.0-24.082
1y Target Est -
DCF Unlevered LRMR DCF ->
DCF Levered LRMR LDCF ->
ROE -58.08% Strong Sell
ROA -60.76% Strong Sell
Operating Margin -
Debt / Equity 19.85% Neutral
P/E -
P/B 2.37 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LRMR news


Dr. Carole S. Ben-Maimon
Healthcare
Biotechnology
Nasdaq Global Select

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.